お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
デフォルト表紙
市場調査レポート
商品コード
1000971

ウロキナーゼ市場調査レポート:タイプ別(ウロキナーゼ粉末、ウロキナーゼ溶液)、用途別(診療所、病院)-2025年までの予測-COVID-19の累積的影響

Urokinase Market Research Report by Type (Urokinase Powder and Urokinase Solution), by Application (Clinic and Hospital) - Global Forecast to 2025 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 197 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.22円
ウロキナーゼ市場調査レポート:タイプ別(ウロキナーゼ粉末、ウロキナーゼ溶液)、用途別(診療所、病院)-2025年までの予測-COVID-19の累積的影響
出版日: 2021年04月12日
発行: 360iResearch LLP
ページ情報: 英文 197 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のウロキナーゼの市場規模は、2020年の22億7,709万米ドルから、2025年末までに26億9,700万米ドルに成長すると予測されています。

COVID-19は、未曾有の世界的な公衆衛生上の緊急事態であり、あらゆる業界に影響を及ぼしてきました。この長期的影響は、予測期間中に業界の成長に影響を与えると予測されています。私たちが進めている調査では、根底にあるCOVID-19の問題と今後の道筋を確実に扱うために、調査範囲を広げています。当レポートは、消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場動向、および政府の重要な介入などを考慮しながら、COVID-19について洞察を提供しています。アップデートされた調査では、COVID-19が市場に及ぼす影響を考慮し、洞察、分析、予測などを提供しています。

当レポートでは、ウロキナーゼ市場について調査し、市場の概要とともに、タイプ別、用途別、地域別の動向、COVID-19の累積的影響、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションと範囲
  • 調査対象年
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査デザイン
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画作成
    • 実行:調査実施
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • イントロダクション
  • 市場の見通し
  • 用途別見通し
  • タイプ別見通し
  • 地域別見通し
  • 競合他社別見通し

第4章 市場概要

  • イントロダクション
  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 世界のウロキナーゼ市場、タイプ別

  • ウロキナーゼ粉末
  • ウロキナーゼ溶液

第7章 世界のウロキナーゼ市場、用途別

  • 診療所
  • 病院

第8章 南北アメリカのウロキナーゼ市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域のウロキナーゼ市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第10章 欧州、中東・アフリカのウロキナーゼ市場

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併と買収
    • 合意、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第12章 企業のユーザビリティプロファイル

  • 4SC AG
  • Eumedica Pharmaceuticals
  • ImaRX Therapeutics
  • Jiangsu Aidea Pharmaceutica
  • Jiangxi Haoran Bio-Pharma
  • Livzon Pharmaceutical Factory of Livzon Group
  • Microbix Biosystems Inc.
  • Nanjing Nanda Pharmaceutical Co. Ltd.
  • NDPharm
  • Salvavidas Pharmaceutical Pvt. Ltd.
  • Shandong PKU High-tech Huatai Pharmaceutical Co. Ltd.
  • Syner-Med Pharmaceuticals
  • Taj Pharmaceuticals Ltd
  • Tianjin Biochemical Pharmaceutical Co. Ltd.
  • Wanhua Biochem
  • Wilex AG
  • Wuhan Humanwell Pharmaceutical Co. Ltd.
  • ZYDUS CADILA HEALTHCARE LTD.

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL UROKINASE MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL UROKINASE MARKET: RESEARCH EXECUTION
  • FIGURE 3. GLOBAL UROKINASE MARKET SIZE, 2020 VS 2025 (USD MILLION)
  • FIGURE 4. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL UROKINASE MARKET SIZE, BY TYPE, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL UROKINASE MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 7. GLOBAL UROKINASE MARKET SIZE, 2018-2025 (USD MILLION)
  • FIGURE 8. GLOBAL UROKINASE MARKET: MARKET DYNAMICS
  • FIGURE 9. GLOBAL UROKINASE MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 10. GLOBAL UROKINASE MARKET SIZE, BY TYPE, 2020 VS 2025 (%)
  • FIGURE 11. GLOBAL UROKINASE MARKET SIZE, BY TYPE, 2020 VS 2025 (USD MILLION)
  • FIGURE 12. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL UROKINASE MARKET SIZE, BY TYPE, 2025
  • FIGURE 13. GLOBAL UROKINASE MARKET SIZE, BY UROKINASE POWDER, 2020 VS 2025 (USD MILLION)
  • FIGURE 14. GLOBAL UROKINASE MARKET SIZE, BY UROKINASE SOLUTION, 2020 VS 2025 (USD MILLION)
  • FIGURE 15. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2020 VS 2025 (%)
  • FIGURE 16. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2020 VS 2025 (USD MILLION)
  • FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2025
  • FIGURE 18. GLOBAL UROKINASE MARKET SIZE, BY CLINIC, 2020 VS 2025 (USD MILLION)
  • FIGURE 19. GLOBAL UROKINASE MARKET SIZE, BY HOSPITAL, 2020 VS 2025 (USD MILLION)
  • FIGURE 20. AMERICAS UROKINASE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 21. AMERICAS UROKINASE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS UROKINASE MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 23. ARGENTINA UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 24. BRAZIL UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 25. CANADA UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 26. MEXICO UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 27. UNITED STATES UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 28. ASIA-PACIFIC UROKINASE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 29. ASIA-PACIFIC UROKINASE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 30. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC UROKINASE MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 31. AUSTRALIA UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 32. CHINA UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 33. INDIA UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 34. INDONESIA UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 35. JAPAN UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 36. MALAYSIA UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 37. PHILIPPINES UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 38. SOUTH KOREA UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 39. THAILAND UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 40. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 41. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 42. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 43. FRANCE UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 44. GERMANY UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 45. ITALY UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 46. NETHERLANDS UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 47. QATAR UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 48. RUSSIA UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 49. SAUDI ARABIA UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 50. SOUTH AFRICA UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 51. SPAIN UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 52. UNITED ARAB EMIRATES UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 53. UNITED KINGDOM UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 54. GLOBAL UROKINASE MARKET: FPNV POSITIONING MATRIX
  • FIGURE 55. GLOBAL UROKINASE MARKET: MARKET SHARE ANALYSIS
  • FIGURE 56. GLOBAL UROKINASE MARKET: COMPETITOR SWOT ANALYSIS
  • FIGURE 57. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL UROKINASE MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. CURRENCY CONVERSION RATES
  • TABLE 2. GLOBAL UROKINASE MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 3. GLOBAL UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL UROKINASE MARKET SIZE, BY UROKINASE POWDER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL UROKINASE MARKET SIZE, BY UROKINASE SOLUTION, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL UROKINASE MARKET SIZE, BY CLINIC, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL UROKINASE MARKET SIZE, BY HOSPITAL, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. AMERICAS UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. AMERICAS UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. AMERICAS UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. ARGENTINA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. ARGENTINA UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. BRAZIL UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. BRAZIL UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. CANADA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. CANADA UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. MEXICO UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. MEXICO UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. UNITED STATES UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. UNITED STATES UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. ASIA-PACIFIC UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. ASIA-PACIFIC UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. ASIA-PACIFIC UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. AUSTRALIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. AUSTRALIA UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. CHINA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. CHINA UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. INDIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. INDIA UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. INDONESIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. INDONESIA UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. JAPAN UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. JAPAN UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. MALAYSIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. MALAYSIA UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. PHILIPPINES UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. PHILIPPINES UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. SOUTH KOREA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. SOUTH KOREA UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. THAILAND UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. THAILAND UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. FRANCE UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. FRANCE UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. GERMANY UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. GERMANY UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. ITALY UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. ITALY UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. NETHERLANDS UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. NETHERLANDS UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. QATAR UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. QATAR UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. RUSSIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. RUSSIA UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. SAUDI ARABIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. SAUDI ARABIA UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. SOUTH AFRICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. SOUTH AFRICA UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. SPAIN UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. SPAIN UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. UNITED ARAB EMIRATES UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. UNITED ARAB EMIRATES UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. UNITED KINGDOM UROKINASE MARKET SIZE, BY APPLICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. UNITED KINGDOM UROKINASE MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. GLOBAL UROKINASE MARKET: SCORES
  • TABLE 69. GLOBAL UROKINASE MARKET: BUSINESS STRATEGY
  • TABLE 70. GLOBAL UROKINASE MARKET: PRODUCT SATISFACTION
  • TABLE 71. GLOBAL UROKINASE MARKET: RANKING
  • TABLE 72. GLOBAL UROKINASE MARKET: MERGER & ACQUISITION
  • TABLE 73. GLOBAL UROKINASE MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 74. GLOBAL UROKINASE MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 75. GLOBAL UROKINASE MARKET: INVESTMENT & FUNDING
  • TABLE 76. GLOBAL UROKINASE MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 77. GLOBAL UROKINASE MARKET: LICENSE & PRICING
目次
Product Code: MRR-54AC507

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global Urokinase Market is expected to grow from USD 2,277.09 Million in 2020 to USD 2,697.00 Million by the end of 2025.

2. The Global Urokinase Market is expected to grow from EUR 1,996.60 Million in 2020 to EUR 2,364.78 Million by the end of 2025.

3. The Global Urokinase Market is expected to grow from GBP 1,774.98 Million in 2020 to GBP 2,102.29 Million by the end of 2025.

4. The Global Urokinase Market is expected to grow from JPY 243,024.10 Million in 2020 to JPY 287,838.37 Million by the end of 2025.

5. The Global Urokinase Market is expected to grow from AUD 3,306.64 Million in 2020 to AUD 3,916.40 Million by the end of 2025.

Market Segmentation & Coverage:

This research report categorizes the Urokinase to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the Urokinase Market studied across Urokinase Powder and Urokinase Solution.

Based on Application, the Urokinase Market studied across Clinic and Hospital.

Based on Geography, the Urokinase Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Urokinase Market including 4SC AG, Eumedica Pharmaceuticals, ImaRX Therapeutics, Jiangsu Aidea Pharmaceutica, Jiangxi Haoran Bio-Pharma, Livzon Pharmaceutical Factory of Livzon Group, Microbix Biosystems Inc., Nanjing Nanda Pharmaceutical Co. Ltd., NDPharm, Salvavidas Pharmaceutical Pvt. Ltd., Shandong PKU High-tech Huatai Pharmaceutical Co. Ltd., Syner-Med Pharmaceuticals, Taj Pharmaceuticals Ltd, Tianjin Biochemical Pharmaceutical Co. Ltd., Wanhua Biochem, Wilex AG, Wuhan Humanwell Pharmaceutical Co. Ltd., and ZYDUS CADILA HEALTHCARE LTD..

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

360iResearch™FPNV Positioning Matrix:

The 360iResearch™ FPNV Positioning Matrix evaluates and categorizes the vendors in the Urokinase Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

360iResearch™Competitive Strategic Window:

The 360iResearch™ Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch™ Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Urokinase Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Urokinase Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Urokinase Market?

4. What is the competitive strategic window for opportunities in the Global Urokinase Market?

5. What are the technology trends and regulatory frameworks in the Global Urokinase Market?

6. What are the modes and strategic moves considered suitable for entering the Global Urokinase Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Stakeholders

2. Research Methodology

  • 2.1. Research Process
    • 2.1.1. Define: Research Objective
    • 2.1.2. Determine: Research Design
    • 2.1.3. Prepare: Research Instrument
    • 2.1.4. Collect: Data Source
    • 2.1.5. Analyze: Data Interpretation
    • 2.1.6. Formulate: Data Verification
    • 2.1.7. Publish: Research Report
    • 2.1.8. Repeat: Report Update
  • 2.2. Research Execution
    • 2.2.1. Initiation: Research Process
    • 2.2.2. Planning: Develop Research Plan
    • 2.2.3. Execution: Conduct Research
    • 2.2.4. Verification: Finding & Analysis
    • 2.2.5. Publication: Research Report
  • 2.3. Research Outcome

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Application Outlook
  • 3.4. Type Outlook
  • 3.5. Geography Outlook
  • 3.6. Competitor Outlook

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cumulative Impact of COVID-19

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of pulmonary embolism globally
      • 5.1.1.2. Usage of urokinase in the treatment of cardiovascular disease
      • 5.1.1.3. Growing instances of Intracerebral hemorrhage
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects caused by urokinase such as Urticaria, difficulty in breathing, and swelling of face, lips, tongue, or throat
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research activities for using urokinase in stroke patients
      • 5.1.3.2. Economic development and substantial infrastructure development
    • 5.1.4. Challenges
      • 5.1.4.1. Urokinase is contraindicated in patients suffering from cancer, brain tumor and high blood pressure
  • 5.2. Porters Five Forces Analysis
    • 5.2.1. Threat of New Entrants
    • 5.2.2. Threat of Substitutes
    • 5.2.3. Bargaining Power of Customers
    • 5.2.4. Bargaining Power of Suppliers
    • 5.2.5. Industry Rivalry

6. Global Urokinase Market, By Type

  • 6.1. Introduction
  • 6.2. Urokinase Powder
  • 6.3. Urokinase Solution

7. Global Urokinase Market, By Application

  • 7.1. Introduction
  • 7.2. Clinic
  • 7.3. Hospital

8. Americas Urokinase Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Urokinase Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. South Korea
  • 9.10. Thailand

10. Europe, Middle East & Africa Urokinase Market

  • 10.1. Introduction
  • 10.2. France
  • 10.3. Germany
  • 10.4. Italy
  • 10.5. Netherlands
  • 10.6. Qatar
  • 10.7. Russia
  • 10.8. Saudi Arabia
  • 10.9. South Africa
  • 10.10. Spain
  • 10.11. United Arab Emirates
  • 10.12. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
    • 11.1.1. Quadrants
    • 11.1.2. Business Strategy
    • 11.1.3. Product Satisfaction
  • 11.2. Market Ranking Analysis
  • 11.3. Market Share Analysis
  • 11.4. Competitor SWOT Analysis
  • 11.5. Competitive Scenario
    • 11.5.1. Merger & Acquisition
    • 11.5.2. Agreement, Collaboration, & Partnership
    • 11.5.3. New Product Launch & Enhancement
    • 11.5.4. Investment & Funding
    • 11.5.5. Award, Recognition, & Expansion

12. Company Usability Profiles

  • 12.1. 4SC AG
  • 12.2. Eumedica Pharmaceuticals
  • 12.3. ImaRX Therapeutics
  • 12.4. Jiangsu Aidea Pharmaceutica
  • 12.5. Jiangxi Haoran Bio-Pharma
  • 12.6. Livzon Pharmaceutical Factory of Livzon Group
  • 12.7. Microbix Biosystems Inc.
  • 12.8. Nanjing Nanda Pharmaceutical Co. Ltd.
  • 12.9. NDPharm
  • 12.10. Salvavidas Pharmaceutical Pvt. Ltd.
  • 12.11. Shandong PKU High-tech Huatai Pharmaceutical Co. Ltd.
  • 12.12. Syner-Med Pharmaceuticals
  • 12.13. Taj Pharmaceuticals Ltd
  • 12.14. Tianjin Biochemical Pharmaceutical Co. Ltd.
  • 12.15. Wanhua Biochem
  • 12.16. Wilex AG
  • 12.17. Wuhan Humanwell Pharmaceutical Co. Ltd.
  • 12.18. ZYDUS CADILA HEALTHCARE LTD.

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.